The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Human Genome Sciences Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Goldberg LLP

Tuesday, July 17, 2012

Human Genome Sciences Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Goldberg LLP15:05 EDT Tuesday, July 17, 2012 LOS ANGELES (Business Wire) -- Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of Human Genome Sciences Inc. (“Human Genome” or the “Company”) (NASDAQ: HGSI) related to the proposed acquisition of the Company by GlaxoSmithKline PLC. The transaction is valued at approximately $3.6 billion or $14.25 per share. This investigation concerns whether the Board of Directors of Human Genome breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Further, at least one analyst has set a target price for the Company's stock at $23.00. If you are a shareholder of Human Genome, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at 310-201-9150 or Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Glancy Binkow & Goldberg LLPLouis Boyarsky, Esquire310-201-9150 or Toll-Free: 888-773-9224shareholders@glancylaw.com